PDCD1 and neoplasm: Indeed, these two studies highlight the existence of two exomiRs (exomiR-125a-5p and exomiR-4315) having different cellular origins (tumor cells and lymphocytes), different mechanisms of action (inhibition of apoptosis and immune escape) but both being potential biomarkers of resistance to anti-PD-1 therapy.